Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC)
Angelo Pirozzi(Humanitas University), Mitesh J. Borad(Jacksonville College), Pedro Luiz Serrano Usón(Hospital Israelita Albert Einstein), Mohamad Bassam Sonbol(WinnMed), Naohiro Okano(Kyorin University), Celine Hoyek(Mayo Clinic Hospital), Tanios Bekaii-Saab, Lorenza Rimassa(Humanitas University), Oluseyi Abidoye(Mayo Clinic)
Cited by 0
Related Papers
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423